Research · PMID 10100178
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
Menopause (New York, N.Y.) · January 1999 · R Kimmerle, L Heinemann, T Heise, R Bender, C Weyer, et al.
What this study found
These results indicate that 3 months use of a low dose continuous E2/NETA preparation does not change insulin sensitivity in postmenopausal women. At high dose of E2/NETA, a modest decrease seems possible.
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Core study
Can hormone therapy help insulin resistance in peri- and postmenopausal women?
Some studies show improved insulin sensitivity with estrogen-based therapy in early postmenopause, but results are not uniform across regimens. HRT should not replace evidence-based diabetes prevention or treatment.
Open evidence analysisSupporting literature
What is the evidence for hormone and metabolic therapy in PCOS?
PCOS management prioritizes lifestyle intervention, cycle regulation, and treatment of hyperandrogenism and metabolic risk. Metformin and hormonal contraceptives have evidence for specific endpoints; individualized plans depend on fertility goals.
Open evidence analysisSupporting literature
Does hormone therapy improve metabolic syndrome markers?
Menopausal hormone therapy may favorably affect some metabolic markers in selected women but is not a primary treatment for metabolic syndrome. Lifestyle and cardiometabolic risk management remain foundational.
Open evidence analysisSupporting literature
Does testosterone therapy affect blood pressure?
Testosterone effects on blood pressure are modest and inconsistent across trials. Monitoring blood pressure remains part of routine TRT follow-up, especially with fluid retention or erythrocytosis.
Open evidence analysisSupporting literature
Do omega-3 supplements prevent cardiovascular disease in the general population?
High-dose EPA (icosapent ethyl) reduced events in selected high-risk statin-treated patients in REDUCE-IT. General over-the-counter omega-3 supplements show inconsistent or null benefit in primary prevention populations.
Open evidence analysisSupporting literature
Should aspirin be used for primary cardiovascular prevention?
Current guidelines generally discourage routine aspirin for primary prevention in low-to-moderate-risk adults because bleeding harm offsets modest benefit. Select high-risk individuals may still be considered with shared decision-making.
Open evidence analysisSupporting literature
Can GLP-1 therapy be combined safely with hormone optimization regimens?
No large outcome trials specifically study combined GLP-1 and hormone therapy. Clinically, combinations are used with attention to muscle mass, nutritional status, and individual cardiometabolic goals.
Open evidence analysisSupporting literature
Does vitamin D supplementation reduce mortality or major disease?
Meta-analyses show vitamin D supplementation does not significantly reduce all-cause mortality in unselected populations. Targeted repletion may benefit those with documented deficiency.
Open evidence analysisSupporting literature
Does magnesium supplementation improve metabolic health markers?
Trials in deficient or at-risk individuals show modest improvements in some glycemic and blood pressure markers, but routine supplementation for metabolic disease prevention is not strongly supported in general populations.
Open evidence analysisSupporting literature
Does DHEA supplementation improve health outcomes in aging adults?
DHEA raises circulating androgens and estrogens modestly but lacks robust outcome trial evidence for cardiovascular, cognitive, or mortality benefit in healthy aging adults without documented deficiency.
Open evidence analysisSupporting literature
When is growth hormone replacement appropriate in adults?
Growth hormone replacement is evidence-supported for adults with confirmed GH deficiency from pituitary disease, improving body composition and quality of life. Use in healthy aging or performance enhancement lacks safety and efficacy evidence.
Open evidence analysis